Intracerebral Hematoma
Conditions
Interventions
ATO:Atorvastatin 20mg 8 weeks+standard treatment of ICH
Control :Standard treatment of ICH
Sponsors
General Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years and over, male and female; 2. GCS > 8, head CT or MRI clearly shows spontaneous, solitary, localized intracerebral hematoma in the basal ganglia (Patients with hematoma volume of 10ml-40ml who were unable to tolerate surgery or refused surgical treatment due to poor function of large organs); 3. Hematoma occurs less than 48 hours; 4. Patients with no risk of brain hernia are suitable for non-surgical treatment; 5. The patient has been acknowledge of the nature of the study, and volunteer to participate in the trial and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patient who is allergic to the drug contents; 2. Within 72 hours, required surgical treatment due to the increased bleeding; 3. Breaking into the ventricle or communicating with the subarachnoid space and cerebrospinal fluid circulation; 4. Hematomas caused herniation or can be highly suspected of causing herniation, non-surgical incurable; 5. Hematoma is caused by tumors, blood diseases, suspected vascular amyloidosis, arteriovenous structural lesions such as aneurysms, arteriovenous malformations and various sinus fistulas; 6. Patients with previous cerebral hemorrhage and neurological dysfunction caused by cerebral infarction; 7. Obvious abnormal function of liver and kidney before the trial, affecting the overall prognosis of patient; 8. Patients with a history of oral or allergic statins during the first 2 weeks of the trial; 9. Use of antiplatelet drugs such as aspirin or warfarin in the last 4 weeks; 10. Patient who has participated in other drug clinical trials in 4 weeks; 11. Pregnancy or lactation patients; 12. Patient with poor compliance, and cannot complete the study according to the research program; 13. The researcher finds there is any situation that is not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The decrease of hematoma;The rate of operation caused by the expansion of hematoma;ADL-BI score;mRS; | — |
Countries
China
Contacts
Public ContactJiang Rongcai
Tianjin Medical University General Hospital
Outcome results
None listed